© 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica In this prospective observational study performed in 12 hospitalized patients with proven or suspected invasive fungal infection treated for a mean of 14 days with micafungin (MCF), 8 of whom with pre-existing liver function impairment, plasma levels of MCF at steady state were not correlated with liver function tests at the beginning of treatment. Liver function remained stable or even improved in all patients, except in one in which MCF was discontinued due to liver toxicity.
- Therapeutic drug monitoring
Luque, S., Campillo, N., Álvarez-Lerma, F., Ferrández, O., Horcajada, J. P., & Grau, S. (2016). Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections. Enfermedades Infecciosas y Microbiologia Clinica, 34(10), 652-654. https://doi.org/10.1016/j.eimc.2015.02.021